weight loss product review v1

Lots of people Try to loss weight, they try many different ways to loss weight by doing exercise, follow diet plans and also some people taking various types of pills for years without any success. But after take too much efforts they didn’t get any success. There are many types products available in the market that help to reduce body weight. But according to the recent survey and all weight loss products are not working some of them are a just rubbish. After the comparison and customers weight loss product reviews we discover a few satisfactory products that actually helps you to reduce your weight without any dieting. Here is a list of top products Acidaburn Lean Belly 3x Okinawa flat belly tonic Revitaa Pro biofit probiotic

Pengaruh Waktu Pengomposan Media Tanam terhadap Pertumbuhan dan Hasil Jamur Tiram Putih (Pleorotus ostreatus)

The cultivation of consumption mushrooms in Indonesia is showing an encouraging development. Currently, Indonesia is included as one of the world's major mushroom suppliers. Mushrooms are a source of vegetable protein that does not contain cholesterol and can prevent high blood pressure, heart disease, diabetes, and can reduce body weight. The research objective was to determine the effect of composting time on planting media on the growth and yield of white oyster mushrooms. The research was conducted in the Mapin Kebak Village, sub-district Alas Barat star from May to June 2020. The research was conducted using an experimental method and using a completely randomized design consisting of 5 treatments, where each treatment consisted of three replications. The research treatments consisted of M1 = composting for 6 hours; M2 = composting for 12 hours; M3 = composting for 24 hours; M4 = composting for 36 hours and M5 = composting for 48 hours. Furthermore, the data from the observations were analyzed by ANOVA at the real level of 5%. If the results of the data analysis show a significant difference, then a further test is carried out using the Least Significant Difference Test at the 5% real level. The results of the analysis showed that the fastest time to spread mycelium was in the M5 treatment, the composting time was 48 hours. The fastest primordia emergence time was 24 hours composting M3 treatment. The heaviest fruit weight was in treatment M3 and the lowest fruit weight was in treatment M1.

How glucagon-like peptide 1 receptor agonists work

Recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of actions, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.

Hepatic Nfe2l2 Is Not an Essential Mediator of the Metabolic Phenotype Produced by Dietary Methionine Restriction

The principal sensing of dietary methionine restriction (MR) occurs in the liver, where it activates multiple transcriptional programs that mediate various biological components of the response. Hepatic Fgf21 is a key target and essential endocrine mediator of the metabolic phenotype produced by dietary MR. The transcription factor, Nfe2l2, is also activated by MR and functions in tandem with hepatic Atf4 to transactivate multiple, antioxidative components of the integrated stress response. However, it is unclear whether the transcriptional responses linked to Nfe2l2 activation by dietary MR are essential to the biological efficacy of the diet. Using mice with liver-specific deletion of Nfe2l2 (Nfe2l2fl/(Alb)) and their floxed littermates (Nfe2l2fl/fl) fed either Control or MR diets, the absence of hepatic Nfe2l2 had no effect on the ability of the MR diet to increase FGF21, reduce body weight and adiposity, and increase energy expenditure. Moreover, the primary elements of the hepatic transcriptome were similarly affected by MR in both genotypes, with the only major differences occurring in induction of the P450-associated drug metabolism pathway and the pentose glucuronate interconversion pathway. The biological significance of these pathways is uncertain but we conclude that hepatic Nfe2l2 is not essential in mediating the metabolic effects of dietary MR.

Protocol for a randomized controlled trial of pre-pregnancy lifestyle intervention to reduce recurrence of gestational diabetes: Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional

Background Gestational diabetes mellitus (GDM) is associated with several maternal complications in pregnancy, including preeclampsia, preterm labor, need for induction of labor, and cesarean delivery as well as increased long-term risks of type 2 diabetes, metabolic syndrome, and cardiovascular disease. Intrauterine exposure to GDM raises the risk for complications in offspring as well, including stillbirth, macrosomia, and birth trauma, and long-term risk of metabolic disease. One of the strongest risk factors for GDM is the occurrence of GDM in a prior pregnancy. Preliminary data from epidemiologic and bariatric surgery studies suggest that reducing body weight before pregnancy can prevent the development of GDM, but no adequately powered trial has tested the effects of a maternal lifestyle intervention before pregnancy to reduce body weight and prevent GDM recurrence. Methods The principal aim of the Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional is to determine whether a lifestyle intervention to reduce body weight before pregnancy can reduce GDM recurrence. This two-site trial targets recruitment of 252 women with overweight and obesity who have previous histories of GDM and who plan to have another pregnancy in the next 1–3 years. Women are randomized within site to a comprehensive pre-pregnancy lifestyle intervention to promote weight loss with ongoing treatment until conception or an educational control group. Participants are assessed preconceptionally (at study entry, after 4 months, and at brief quarterly visits until conception), during pregnancy (at 26 weeks’ gestation), and at 6 weeks postpartum. The primary outcome is GDM recurrence, and secondary outcomes include fasting glucose, biomarkers of cardiometabolic disease, prenatal and perinatal complications, and changes over time in weight, diet, physical activity, and psychosocial measures. Discussion The Gestational Diabetes Prevention /Prevención de la Diabetes Gestacional is the first randomized controlled trial to evaluate the effects of a lifestyle intervention delivered before pregnancy to prevent GDM recurrence. If found effective, the proposed lifestyle intervention could lay the groundwork for shifting current treatment practices towards the interconception period and provide evidence-based preconception counseling to optimize reproductive outcomes and prevent GDM and associated health risks. Trial registration ClinicalTrials.gov NCT02763150. Registered on May 5, 2016

Protocol for a randomized controlled trial of pre-pregnancy lifestyle intervention to reduce recurrence of gestational diabetes: Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional

BackgroundGestational diabetes mellitus (GDM) is associated with several maternal complications in pregnancy, including preeclampsia, preterm labor, need for induction of labor, and cesarean delivery as well as increased long-term risks of type 2 diabetes, metabolic syndrome, and cardiovascular disease. Intrauterine exposure to GDM raises the risk for complications in offspring as well, including stillbirth, macrosomia, and birth trauma and long-term risk of metabolic disease. One of the strongest risk factors for GDM is the occurrence of GDM in a prior pregnancy. Preliminary data from epidemiologic and bariatric surgery studies suggest that reducing body weight before pregnancy can prevent development of GDM, but no adequately powered trial has tested the effects of a maternal lifestyle intervention before pregnancy to reduce body weight and prevent GDM recurrence.MethodsThe principal aim of Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional is to determine whether a lifestyle intervention to reduce body weight before pregnancy can reduce GDM recurrence. This two-site trial targets recruitment of 252 women with overweight and obesity who have previous histories of GDM and who plan to have another pregnancy in the next 1–3 years. Women are randomized within site to a comprehensive pre-pregnancy lifestyle intervention to promote weight loss with ongoing treatment until conception or an educational control group. Participants are assessed preconceptionally (at study entry, after 4 months, and at brief quarterly visits until conception), during pregnancy (at 26 weeks’ gestation) and at 6 weeks postpartum. The primary outcome is GDM recurrence and secondary outcomes include fasting glucose, biomarkers of cardiometabolic disease, prenatal and perinatal complications, and changes over time in weight, diet, physical activity and psychosocial measures.DiscussionGestational Diabetes Prevention /Prevención de la Diabetes Gestacional is the first randomized controlled trial to evaluate the effects of a lifestyle intervention delivered before pregnancy to prevent GDM recurrence. If found effective, the proposed lifestyle intervention could lay the groundwork for shifting current treatment practices towards the interconception period and provide evidence-based preconception counseling to optimize reproductive outcomes and prevent GDM and associated health risks.Trial registrationClinicalTrials.gov Identifier: NCT02763150

Hand-to-mouth Consumption and Calorie Consciousness: Consequences for Junk-food Taxation

Junk-food taxes have mixed effects on obesity and junk-food consumption. We build a theoretical model to explain empirical results and better understand how to address the obesity crisis. In our framework, hand-to-mouth consumers make an intertemporal choice between junk-food consumption and weight loss. Their choice depends on calorie consciousness, which is influenced by perceived after-tax relative prices and educational attainment. Thus, a junk-food tax modifies consumers’ intertemporal choice both through their budget constraint and calorie consciousness. As a result, the effect of the tax on body weight reflects competing income, intertemporal substitution, and calorie-consciousness effects. The model explains empirical observations such as the recent rise in obesity and differences in weight outcomes for different income levels. The model explains circumstances under which junk-food taxes can be effective or ineffective to reduce body weight as well as differences in elasticities of high-calorie food consumption for high- and low-income earners.

Modern approaches to pharmacotherapy of non-alcoholic fatty liver disease

According to the forecasts of the World Health Organization, non-alcoholic fatty liver disease (NAFLD) will rank first in the structure of liver diseases by 2020. The article presents the current provisions on the pathogenesis of NAFLD, as well as existing and promising directions in the treatment of non-alcoholic fatty liver disease. A review of the recommendations of the leading hepatological associations for the treatment of non-alcoholic fatty liver disease is carried out. The main directions in the pharmacological treatment of NAFLD are the prescription of drugs that reduce body weight, increase the sensitivity of tissues to insulin, affect oxidative stress, normalize the levels of lipids and blood transaminases, and correct intestinal microflora.

State-of-the-Art Drug Therapies of Obesity

Objective of the Review: To discuss state-of-the-art drug therapies of obesity. Key Points. Obesity is a socially significant healthcare problem, because it is associated with major conditions limiting life expectancy. The problem of obesity dates back to the period of Hippocrates; however, efficient drugs appeared as late as in the ХХI century. The article is a review of the state-of-the-art drug therapies for body weight reduction approved in the Russian Federation. It describes the efficiency and side effects and a case of obesity management with Liraglutide 3mg. Conclusion. Obese and overweight patients should undergo a medical examination in order to verify associated conditions and prescribe treatment, including drug therapy to reduce body weight. Keywords: obesity, drug therapy, body mass index, Liraglutide.